CY: “It will depend on the percentage of thrombocytes that are suitable for the system. We are producing THERAFLEX UV-Platelets on a small scale, exclusively for the use within a clinical trial. For routine production, the specifications for the volume, concentration and protein content of the thrombocytes would need to be a bit broader.
I know that Prof. Axel Seltsam and his team are working to broaden the specification..
100% pathogen reduction for platelet concentrates while maintaining acceptable platelet function would solve some problems and lead to a higher quality of blood product, as there are still incidents of bacterial contamination of concentrate and it would be very helpful if we could improve in this area.”